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Context: Resveratrol exhibits colon cancer prevention activity in animal models; it is purported 
to have this activity in humans and inhibit a key signaling pathway involved in colon cancer 
initiation, the Wnt pathway, in vitro.
Design: A phase I pilot study in patients with colon cancer was performed to evaluate the effects 
of a low dose of plant-derived resveratrol formulation and resveratrol-containing freeze-dried 
grape powder (GP) on Wnt signaling in the colon. Eight patients were enrolled and normal colonic 
mucosa and colon cancer tissue were evaluated by Wnt pathway-speciﬁ  c microarray and quantita-
tive real-time polymerase chain reaction (qRT-PCR) pre- and post-exposure to resveratrol/GP.
Results: Based on the expression of a panel of Wnt target genes, resveratrol/GP did not inhibit 
the Wnt pathway in colon cancer but had signiﬁ  cant (p  0.03) activity in inhibiting Wnt target 
gene expression in normal colonic mucosa. The greatest effect on Wnt target gene expression 
was seen following ingestion of 80 g of GP per day (p  0.001). These results were conﬁ  rmed 
with qRT-PCR of cyclinD1 and axinII. The inhibitory effect of GP on Wnt signal throughput 
was conﬁ  rmed in vitro with a normal colonic mucosa-derived cell line.
Conclusions: These data suggest that GP, which contains low dosages of resveratrol in com-
bination with other bioactive components, can inhibit the Wnt pathway in vivo and that this 
effect is conﬁ  ned to the normal colonic mucosa. Further study of dietary supplementation with 
resveratrol-containing foods such as whole grapes or GP as a potential colon cancer preventive 
strategy is warranted.
Trial registration: NCT00256334.
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Introduction
Colon cancer is the third leading cause of cancer deaths among men and women in the 
United States.1 The epidemiology of colon cancer suggests that dietary factors play 
a critical role in tumor initiation and promotion,2 with populations consuming a diet 
high in ﬁ  ber, vegetables, and fruits exhibiting a lower cancer incidence. Recent dietary 
recommendations for cancer prevention highlight the importance of a plant-based diet 
in the prevention of several types of cancer.3,4
Resveratrol is a stilbene found in the skin of grapes, red wine, peanuts, and 
some other plant species. In vitro, this agent has been shown to have antioxidant 
activity and proapoptotic activity, and to inhibit proliferation of colon cancer cell 
lines.5 The data for prevention of colon cancer by resveratrol in animal models 
are somewhat contradictory, both in its efﬁ  cacy as well as information regarding 
the effective dose range. Tessitore6 demonstrated activity of a very low dose 
resveratrol of 0.2 mg/kg/day in reducing aberrant crypt foci (ACF) in the colon Cancer Management and Research 2009:1 26
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in an azoxymethane-induced tumor model. In another 
carcinogen-based model, utilizing 1,2-dimethylhydrazine, 
resveratrol in a dose of 8 mg/kg/day reduced both ACF and 
colonic tumors.7,8 In genetic models utilizing the APCmin/+ 
mouse, which harbors a single allele mutation in apc, 
and therefore has intrinsically activated Wnt signaling, 
Schneider9 demonstrated profound activity at dosages as 
low as 0.3 mg/mouse/day in reducing intestinal tumors. In 
this study, expression of cyclinD1, a Wnt target gene, as 
well as other markers of cell cycling, was reduced. Other 
studies10–12 have found resveratrol to be ineffective or 
effective only at high dosages in inducing a more modest 
reduction in intestinal tumorigenesis. Overall, these studies 
indicate that resveratrol may have activity for colon cancer 
prevention in both carcinogen-induced tumor models as 
well as in the Wnt-activated APCmin/+ mouse, but that the 
effective dose is unclear.
Resveratrol is also reported to inhibit ribonucleotide 
reductase in leukemia cell lines,13 DNA polymerase in 
fibroblasts,14 ornithine decarboxylase in mouse hepatic 
tissue,15 and IkappaB kinase in monocyte cell lines and mouse 
skin.16,17 Activation of SIRT1 (sirtuin-1) is thought to be an 
important mechanism through which resveratrol exerts anti-
aging activity.18 While inhibition of IkappaB kinase and DNA 
polymerase can be seen at concentrations as low as 1 μM, 
SIRT1 activation and inhibition of other target enzymes gen-
erally requires concentrations between 50 μM and 100 μM, 
demonstrating that this compound has differential effects 
over at least a 100× concentration range.
In relation to the cancer chemopreventive effects, the 
concentrations attained in vivo are signiﬁ  cantly lower than 
the concentrations required for inhibition of cell growth 
in vitro, raising the question as to how resveratrol exhibits this 
activity in animal models and perhaps in humans.19 A recent 
pharmacokinetic study of single dose resveratrol conﬁ  rmed 
that peak plasma concentrations of the parent compound 
following a single large 5 g ingestion reached only 539 ng/ml 
(2.4 μM).20 However, the peak levels of resveratrol-3-sulfate 
and two monoglucuronides were three to eight times higher, 
raising the possibility that cancer prevention activity may be, 
at least in part, attributable to resveratrol’s principal metabo-
lites. Other explanations of resveratrol’s in vivo activity may 
be that, even though serum concentrations are low, local 
concentrations in the gut are sufﬁ  cient to provide activity. 
Alternatively, resveratrol’s activity may be augmented by, 
or at low concentration be dependent upon cooperativity 
with other bioactive compounds present in dietary sources 
such as grapes.
The Wnt signaling pathway is critically important in 
the development of colon cancer, with activating mutations 
seen in over 85% of sporadic cases.21 Mutations in either apc 
or β-catenin are early events which constitutively activate 
the pathway22 promoting cell growth and proliferation and 
inhibiting normal patterns of colonic stem cell differentia-
tion.23 Prior studies have demonstrated that relatively low 
concentrations (10 μM–20 μM) of resveratrol can inhibit 
Wnt signal throughput in colon-derived cells in vitro.24,25 This 
may be one of the potential mechanisms by which resveratrol 
provides colon cancer prevention activity in vivo. To evaluate 
this directly, a phase I pilot clinical trial of low dose, plant-
derived resveratrol and resveratrol-containing freeze-dried 
grape powder (GP) was initiated in patients with colon cancer. 
Our hypothesis was that resveratrol and resveratrol-contain-
ing GP would inhibit Wnt signaling in vivo in both the normal 
colonic mucosa and cancer tissue. This trial, with biomarker 
endpoints evaluating the expression of multiple components 
and target genes of the Wnt pathway, represents the ﬁ  rst 
reported clinical trial of resveratrol in patients with cancer. 
We demonstrate here that both plant-derived resveratrol and 
GP have effects in vivo on various measures of the Wnt path-
way in colon cancer and normal colonic mucosa. Resveratrol 
in combination with other bioactive components present in 
GP had a signiﬁ  cant effect on suppressing Wnt pathway target 
gene expression, a measure of Wnt signal throughput, in nor-
mal colonic mucosa suggesting their potential incorporation 
into colon cancer prevention strategies.
Experimental methodology
Clinical protocol
Patients with suspected or documented colorectal cancer were 
identiﬁ  ed through clinics at the H.H. Chao Digestive Diseases 
Center and the Chao Family Comprehensive Cancer Center 
at the University of California, Irvine. All patients completed 
written informed consent and enrolled onto an Institution 
Review Board-approved clinical trial. The clinical trial was 
registered with clinicaltrials.gov prior to study initiation 
(NCT00256334). Between September 22, 2005 and July 5, 
2008, eight patients were enrolled onto the study. Since most 
patients diagnosed with colon cancer by sigmoidoscopy or 
colonoscopy do not undergo additional endoscopic examina-
tion prior to surgical resection, accrual was hampered by the 
necessity for obtaining fresh normal and tumor tissue prior to 
biopsy conﬁ  rmation of cancer. Charts for over 250 patients 
scheduled for colonoscopic examination were screened. 
More than 50 individuals were identiﬁ  ed as potential colon 
cancer patients and were enrolled onto the tissue acquisition Cancer Management and Research 2009:1 27
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component of this study. Of these, 11 patients were diagnosed 
with cancer and eight agreed to participation in the resveratrol/
GP intervention prior to surgery. The initial target enrollment 
was 12 patients; three patients were to be randomized to four  
dose cohorts. Because of slow enrollment related to the study 
design, this study was closed after eight patients completed 
the intervention. The study was an open label phase I pilot 
study with biomarker endpoints.
At the time of diagnostic colonoscopy for suspected colon 
cancer, tissue biopsies were obtained from cancer tissue and 
normal colonic mucosa. Matched specimens for each were 
reviewed by pathology to conﬁ  rm the histologic diagnosis. 
Tissue was placed into RNAlater® (Applied Biosystems, 
Foster City, CA) and total RNA was later isolated with a 
Trizol reagent. Patients then received 14 days of resveratrol 
or freeze-dried GP until the day prior to surgery for colon 
cancer resection. The 14-day treatment period was selected 
because the typical delay from diagnosis to elective surgical 
resection was 14 to 16 days at our institution. If participa-
tion in the study would have necessitated a delay in surgery, 
then enrollment was not permitted. Patients were randomly 
assigned to one of four dose cohorts: plant-derived resveratrol 
tablets (purchased through the Life Extension Foundation, 
Scottsdale, AZ) at a dose of 80 mg/day, plant-derived 
resveratrol tablets at a dose of 20 mg/day, GP dissolved in 
water and taken orally (supplied by the California Table 
Grape Commission) at a dose of 120 g/day, and GP at a 
dose of 80 g/day (Table 1). This latter dose is equivalent 
to approximately 0.45 kg of fresh grapes/day (three United 
States Department of Agriculture (USDA)- recommended 
servings/day). At the time of surgical resection, biopsies 
from the cancer and normal colonic mucosa were obtained 
and processed identically to the pretreatment specimens.
Resveratrol capsules were obtained from Life Extension 
Corporation as a plant-derived nutritional supplement 
containing 20 mg trans-resveratrol per capsule derived from 
whole red grapes and Polygonum cuspidatum root extracts. 
Each capsule also had 120 mg of quercetin as quercetin 
dehydrate. High-pressure liquid chromatography (HPLC) 
analysis of the 20 mg capsules revealed only 3.886 mg of 
trans-resveratrol (personal communication, Dr Arthur S 
Polans, University of Wisconsin). Freeze-dried GP was 
obtained from the California Table Grape Commission. 
It is a composite of fresh red, green, and blue-black 
California grapes (seeded and seedless varieties), that were 
frozen, ground with food-quality dry ice, freeze-dried, 
and reground using good manufacturing practices for 
food products throughout. The powder was processed and 
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stored to preserve the integrity of the biologically-active 
compounds found in fresh grapes. As with fresh grapes, the 
powder is known to contain resveratrol, ﬂ  avans (including 
catechin), ﬂ  avonols (including quercetin), anthocyanins 
and simple phenolics. Detailed analysis of the GP revealed 
resveratrol, 4 μM/kg of dry powder; ﬂ  avonols,118 μM/kg; 
anthocyanins,700 mg/kg; ﬂ  avans, 3.9 mg/g (as catechin); 
and total phenols, 6.2 mg/g. Total phenols were analyzed by 
reaction with Folin and Ciocalteu’s phenol reagent; ﬂ  avans 
were analyzed by reaction with vanillin; anthocyanins were 
analyzed spectrophotometrically; ﬂ  avonols and resveratrol 
were analyzed by HPLC after acid hydrolysis.
Microarray pre- and post-specimen cDNA was analyzed 
with a GEArray Q Series Human Wnt Signaling Pathway 
Gene Array (SuperArray Bioscience, Frederick, MD) which 
is designed to systematically proﬁ  le the expression of genes 
involved in and downstream of Wnt signaling. The array 
includes the Wnt ligands and their receptors, intracellu-
lar signaling molecules, and representative target genes. 
Pre-resveratrol/GP samples were compared side-by-side 
to post-resveratrol/GP samples from the same patient to 
deﬁ  ne changes in gene expression. The GEArray expression 
analysis software was utilized to enable background normal-
ization, correction for different degrees of exposure, and 
normalization with multiple housekeeping gene controls on 
each membrane. Insufﬁ  cient RNA was available to conduct 
microarray analysis from one patient (80 mg/day resveratrol 
tablets) though samples from this patient were analyzed by 
quantitative real-time polymerase chain reaction (PCR).
Quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was utilized to deﬁ  ne 
the expression of cylinD1, axinII, and myc. Speciﬁ  c primer 
sets for each gene were employed and expression was com-
pared to actin controls in all cases. Primer pairs were obtained 
from Qiagen (Valencia, CA), catalog numbers QT00495285, 
QT00037639, QT00035406, and QT00095431. qRT-PCR 
was also utilized to examine changes in the expression of 
two colonic stem cell markers, CD133 and LGR5 (GPR49). 
We utilized a previously described primer pair for CD133: 
forward: 5´-GCATTGGCATCTTCTATGGTT-3´, reverse: 
5´-CGCCTTGTCCTTGGTAGTGT-3´,26 and Quiagen prim-
ers for LGR5, catalog number QT00027720. For qRT-PCR 
experiments, the relative RNA expression was calculated 
by the comparative threshold cycle method utilizing SYBR 
Green reagents (Applied Biosystems) and an ABI Prism7000 
Sequence Detection System. Reaction conditions for CD133: 
50 cycles at 95 °C–30 s; 55 °C–30 s; 60 °C–30 s. Reaction 
conditions for Qiagen primers: 50 cycles of 95 °C–15 s; 
55 °C–30 s; 60 °C–30 s.
In vitro analyses
Resveratrol-induced changes in the expression of c-myc were 
deﬁ  ned by qRT-PCR in RKO colon cancer cells (American 
Type Culture Collection, Manassas, VA). This cell line, origi-
nally obtained from a patient with hereditary nonpolyposis 
colon cancer, displays microsatellite instability (MSI, or 
RER(+)) and has no known Wnt pathway activation. It was 
maintained in culture in RPMI1640 media at 5% CO2 with 
10% fetal bovine serum (FBS). Pure trans-resveratrol was 
obtained from Sigma-Aldrich (St. Louis, MO) and a stock 
solution was prepared in dimethyl sulfoxide (DMSO). Final 
concentrations of resveratrol for the experiments were 10 μM 
and 20 μM with  1% v/v DMSO. Exposure time to resve-
ratrol was 48 hours. The same primers that were used for the 
tissue-based experiments, as described above, were used.
To deﬁ  ne the effect of GP on Wnt signal throughput in vitro, 
a normal colon-derived cell line, NCM460 was used. NCM460 
was obtained from Incell Corporation (San Antonio, TX).27 
This cell line was maintained in M3 Base cell culture medium 
complete (catalog number M300A-500; Incell) with 10% FBS. 
For these studies, 1.3 grams of GP was extracted into 30 mL 
of 100% ethanol by a modiﬁ  cation of the method of Cho and 
colleagues.28 Brieﬂ  y, the GP suspension in ethanol was soni-
cated for ﬁ  ve minutes using a bath type 47 KHz Bransonic 
1510 ultrasonic processor. Insoluble material was removed by 
centrifugation at 10,000 × g for 15 minutes. Ethanol extracts 
were stored at −20 °C. 1-mL aliquots were processed to dryness 
in a SpeedVac DNA110. Each aliquot contained approximately 
16 mg of solid material. Stock solutions of 40 mg/ml were 
prepared in 93% DMSO, 7% water.
Wnt throughput was defined using a Wnt pathway 
reporter construct containing seven LEF/TCF consensus 
binding sites preceding a secreted alkaline phosphatase 
(7X-SEAP) reporter.25 Activation of Wnt signaling leads 
to production of SEAP which is secreted into the culture 
media. Cells were typically between 70% to 90% conﬂ  uent 
on the day of transfection. Reporter plasmid DNA, 1.2 μg 
and 0.12 μg of LEF1 expression construct, and/or inactive 
DNA (pBluescript) for a total mass of 1.44 μg DNA per 
well was transfected using Lipofectamine 2000 (Invitrogen, 
Calsbad, CA) following manufacturer’s recommendations. 
LEF1 was used to augment basal Wnt pathway activity 
in order to facilitate the detection of potential GP extract-
induced pathway inhibition. Each condition was performed 
in triplicate. After 48 hours, media was recovered and 20 μL Cancer Management and Research 2009:1 29
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was assayed using Great EscAPe SEAP detection kit (BD 
Biosciences, San Jose, CA) in a 96-well format. Plates were 
read on a ML3000 microtiter plate luminometer (Dynatech 
Laboratories, Chantilly, VA). Experiments were performed 
with and without 60 μg/ml GP extract and all experiments 
were performed in conjunction with transfection of a SEAP 
plasmid lacking LEF/TCF binding sites as a control.
Statistics
Pre- and post-resveratrol/GP expressions of individual genes 
by microarray were compared for all participants at each 
dose level on the clinical protocol with a two-tailed paired 
t-test. Composite target gene expression comparisons used 
a two-tailed unpaired t-test. Gene expression by qRT-PCR 
and Wnt throughput SEAP activity values were compared in 
individual cohorts with a two-tailed unpaired t-test. Levels 
of signiﬁ  cance were deﬁ  ned as α  0.05.
Results
Clinical trial monitoring
No patients experienced any toxicities while enrolled on the 
clinical trial, regardless of whether they received resveratrol 
tablets or the freeze-dried GP. Speciﬁ  cally, there were no 
reported changes in bowel habits (diarrhea or constipation), 
no abdominal bloating, no nausea or vomiting, and no gas-
trointestinal bleeding.
Expression of Fz receptors, Wnt ligands, 
and Wnt inhibitors in normal mucosa 
and colon cancer
The expression of Wnt ligands and numerous Wnt inhibi-
tory genes of the soluble frizzled-related protein (sFRP), 
dikkopf (DKK) and Wnt inhibitory factor (WIF) families 
was not statistically different between normal mucosa and 
colon cancer (Figure 1). In cancer, several Fz receptors had 
increased expression, including Fz1, Fz2, Fz3, Fz4, Fz6, 
Fz7, and Fz10, but only the expression of Fz2 was statisti-
cally signiﬁ  cant (p  0.05; Figure 1A). There were trends 
for increased Wnt ligand expression (Figure 1B) in cancer, 
including Wnt1, Wnt2, Wnt3a, Wnt10a, and Wnt11 and for 
several of the Wnt inhibitory genes (Figure 1C), but none of 
these reached statistical signiﬁ  cance.
Wnt target genes in normal mucosa 
and colon cancer
Wnt pathway target gene expression was uniformly higher in 
cancer than in normal mucosa (Figure 2A). The composite 
target gene expression, including LEF1, myc, jun, nemo, 
Tcf7, cyclinD1, FGF4, and axinII, was 350% higher in cancer 
than in normal tissue (p = 0.002; Figure 2B), indicating 
activated Wnt signaling in the cancer tissue. Our data also 
conﬁ  rms minimal expression of LEF1 in normal mucosa with 
increased expression in colon cancer (p = 0.07; Figure 2A), 
as we have reported previously using different experimental 
methodologies.29 Wnt pathway activation in colon cancer 
compared to normal colonic mucosa was confirmed by 
qRT-PCR (Figure 2C) which demonstrated increased expres-
sion of cyclinD1 (p = 0.001) and axin II (p  0.001). The 
expression of myc was increased in cancer but the difference 
of expression compared to normal mucosa was not statisti-
cally signiﬁ  cant.
Effect of resveratrol/GP on Wnt target 
gene expression in colon cancer
In cancer tissue, resveratrol/GP treatment led to no change 
or a slight increase in most of the Wnt pathway target 
genes (Figure 3). The microarray data (Figure 3A) sug-
gested increases in myc and cyclinD1 expression, with 
slight decreases seen for LEF1, nemo, TCF7 and FGF4. 
AxinII, and jun expression were unchanged. Composite 
target gene expression by microarray following exposure 
to resveratrol/GP was unchanged in colon cancer tissue 
when compared to the pretreatment baseline (Figure 3B). 
Conﬁ  rmatory qRT-PCR (Figure 3C) of the cancer tissue 
pre- and post-resveratrol 80 mg/day (R80) and GP 80 g/day 
(GP80) demonstrated signiﬁ  cant increases in expression 
for both myc and cyclinD1. These increases were greatest 
following GP80 and reached statistical signiﬁ  cance (p  0.01 
and p  0.05, respectively).
Effect of resveratrol/GP on Wnt target 
gene expression in normal mucosa
In normal colonic mucosa, resveratrol/GP treatment resulted 
in a decrease in most of the Wnt target genes evaluated by 
microarray (Figure 4A), including myc, jun, TCF7, axinII, 
and cyclinD1. The composite target gene expression by 
microarray in the normal mucosa was signiﬁ  cantly reduced 
following exposure to resveratrol/GP (Figure 4B) when 
all treatment groups were combined (p = 0.03) though the 
most signiﬁ  cant reduction in Wnt target gene expression 
was seen at the lower dose of GP (GP80, p  0.001). The 
reduction in cyclinD1 (p  0.005) and axinII (p  0.05) 
following exposure to GP80 were conﬁ  rmed by qRT-PCR 
(Figure 4C). No signiﬁ  cant differences were seen in cyclinD1 
and axinII expression following exposure to R80. The one Cancer Management and Research 2009:1 30
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target gene for which a decrease in expression following 
GP80 could not be conﬁ  rmed was myc. By qRT-PCR, myc 
was paradoxically increased (p = 0.01).
Effect of resveratrol/GP on stem cell 
markers
Because the greatest reduction in Wnt signaling appeared 
to occur following exposure to GP80, and because colonic 
stem cell proliferation is regulated in part by Wnt signals, 
the effect of GP80 on two colonic stem cell markers, 
CD133 and LGR5 (GPR49), was evaluated by qRT-PCR 
(Figure 5). Overall, CD133 and LGR5 expression was higher 
in cancer than in normal mucosa (p  0.05 and p  0.005, 
respectively, data not shown) and no signiﬁ  cant change in 
expression was seen following GP80. However, following 
exposure to GP80, CD133 expression in normal mucosa 
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was decreased (p  0.05) as was the expression of LGR5 
(trend, p = 0.09).
In vitro effect of resveratrol 
on myc expression
Because the effect of resveratrol/GP on myc expression was 
paradoxically opposite of its effect on other Wnt target genes, 
we examined the effect of resveratrol on myc expression in 
RKO colon cancer cells in vitro. Resveratrol is known to 
inhibit Wnt signaling in RKO cells in vitro at concentrations 
as low as 10 μM and 20 μM.25 By qRT-PCR, myc expression 
increased in a dose-dependent fashion following exposure 
to 10 μM and 20 μM resveratrol to over 300% of control 
(Figure 6A).
In vitro effect of GP on Wnt signal 
throughput
Because the reduction in Wnt target gene expression was 
greatest for GP80, which contained the lowest amounts of 
resveratrol in any of the treatment groups but contained 
numerous bioactive components not present within the plant-
derived resveratrol formulation, the ability of GP to directly 
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Figure 3 Target gene expression in colon cancer prior to (CA) and following (CA-R/GP) exposure to resveratrol or freeze-dried grape powder. Panel A depicts microarray 
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inhibit Wnt signaling in vitro was evaluated with a reporter 
construct containing LEF/TCF binding sites. Additionally, 
since the effect of GP80 in the clinical trial was conﬁ  ned 
to normal colonic mucosa, the normal colon-derived cell 
line NCM460 was used for these experiments. As can be 
seen in Figure 6B, GP signiﬁ  cantly inhibited Wnt pathway 
throughput to nearly half of the baseline activity in NCM460 
cells (p  0.005).
Discussion and conclusions
Based on the microarray results from patients enrolled onto 
the clinical trial, no major differences in the expression 
between normal colonic mucosa and colon cancer were seen 
for the frizzled receptors, Wnt ligands or soluble Wnt inhibi-
tory molecules, with the possible exception of Fz2 which 
exhibited higher levels of expression in cancer tissue. Sev-
eral of these molecules exhibited trends toward differential 
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expression which could be investigated by more sensitive 
methodologies such as qRT-PCR in future studies. Of note, 
LEF1, a downstream transcriptional regulator for the Wnt 
pathway, was minimally expressed in normal mucosa but 
showed increased expression in cancer which is consistent 
with prior observations.29,30 In addition to being an integral 
component of the pathway, LEF1 is also a Wnt target gene31 
which may account for the increased expression in cancer 
that was observed here.
Our microarray data of Wnt target gene expression 
suggests that colon cancers exhibit increased Wnt through-
put compared to normal mucosa, consistent with the known 
activation of Wnt signaling in the majority of colorectal 
cancers.21 These ﬁ  ndings were conﬁ  rmed with qRT-PCR 
of cyclinD1 and axinII, two well characterized Wnt target 
genes.32,33 Colon cancers also exhibited higher levels of 
expression of CD133, which is purported to be a marker of 
colon cancer stem cells34 and is, itself, a Wnt target gene. 
Interestingly, no differences in myc expression between 
normal and cancer could be conﬁ  rmed by qRT-PCR.
Patients treated with resveratrol/GP had no change over-
all in the composite Wnt target gene expression in colon 
cancer. Several of the genes, including myc and cyclinD1, 
increased in the cancer tissue following the two-week 
exposure to GP80, though no statistically signiﬁ  cant change 
was seen following exposure to R80. The mechanism 
for these increases is unclear and will necessitate further 
investigation and also caution in promoting the use of 
plant-derived resveratrol or resveratrol foodstuffs with 
therapeutic intent for colon cancer patients. Additionally, 
target gene expression is only an indirect indicator of Wnt 
signal throughput and even if Wnt signaling was suppressed, 
other regulatory pathways may be responsible for increases 
in myc and cyclinD1 expression. Alternatively, cancer 
therapeutic-oriented effects might also be seen at higher 
concentrations obtained with pharmacologic dosages of 
pure trans-resveratrol. Certainly in vitro,5 high concen-
trations of resveratrol result primarily in proliferation-
inhibiting and apoptosis-inducing effects.
Resveratrol and GP appear to have quite a different 
effect on normal colonic mucosa, where inhibition of Wnt 
target gene expression is seen by microarray and conﬁ  rmed 
by qRT-PCR of cyclinD1 and axinII. The greatest effect 
was seen with GP80 which had the lowest resveratrol 
content of all the cohorts but many other bioactive compo-
nents not present in the plant-derived resveratrol capsules. 
This amount of GP is equivalent to ingestion of 0.45 kg 
of fresh grapes per day, or approximately three USDA 
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Figure 5 Expression of colonic stem cell markers CD133 and LGR5 (GPR49) in normal colonic mucosa prior to (NL) and following (NL-GP80) exposure to freeze-dried 
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servings. This is an amount which is dietarily achievable 
and represents an extremely low dose of resveratrol itself. 
Expression of both CD133 and LGR5, markers of colon 
cancer and colonic stem cells, and Wnt target genes,34,35 
decreased in normal mucosa following exposure to GP80 
though the change in LGR5 did not reach statistical sig-
niﬁ  cance. The inﬂ  uence of GP on Wnt signal throughput 
was tested directly in vitro with normal mucosa-derived 
NCM460 cells. After 48 hours of incubation, signiﬁ  cant 
inhibition of Wnt signal throughput was noted. This is 
despite an extremely low resveratrol concentration in 
the reconstituted GP (4 μM/kg dry weight). The greater 
effect seen with GP, compared to resveratrol, suggests that 
the effect on Wnt target gene expression and Wnt signal 
throughput is due to coopertivity of resveratrol with other 
bioactive ﬂ  avonoids and polyphenols in grapes, rather 
than to resveratrol alone. In addition, the Wnt inhibitory 
effect in normal mucosa suggests that GP or resveratrol-
containing foods may have more clinical utility for colon 
cancer prevention rather than for treatment of established 
colon cancer.
Based on our results, myc does not appear to be a good 
marker for Wnt pathway activation, possibly because of 
potential effects of resveratrol on other pathways involved 
in regulation of myc expression such as those mediated by 
NF-κB and or initiated following activation of tyrosine 
kinase growth factor receptors.36 An increase in myc was 
conﬁ  rmed in vitro in colon cancer cells with low concen-
trations of trans-resveratrol which are known to inhibit 
Wnt signal throughput.25 Interestingly, while increased 
myc expression would generally be considered detrimental 
in cancer, due to its pro-proliferative effects, increased 
expression in normal mucosa, where cells have intact 
p53-mediated apoptotic pathways, can result in induction 
of apoptosis rather than proliferation.37 Further study of 
the colonic mucosal proliferative response to resveratrol 
or GP, with correlation to myc and cyclinD1 expression 
levels, are indicated.
There are several characteristics of this study which 
dictate caution before generalizing the ﬁ  ndings. This was a 
pilot study with a small number of participants which could 
account for variability in the expression levels of molecular 
markers as well as the lack of statistically signiﬁ  cant altera-
tions observed. For the microarray data, multiple compari-
sons were performed for individual groups so the level of 
statistical stringency is critical, though conﬁ  rmation by qRT-
PCR partially mediates this concern. No attempt was made 
to control for dietary intake of the participants during the 
two-week treatment period and no food recall to determine 
whether participants ingested resveratrol-rich foods during 
this period was performed. Additionally, it was not recorded 
whether other confounding medications which might affect 
the Wnt pathway, such as nonsteroidal anti-inﬂ  ammatory 
medications, were ingested.
Despite these limitations, this is the ﬁ  rst reported trial 
of resveratrol/GP in cancer patients. Low dosages of res-
veratrol in combination with other bioactive compounds 
in GP inhibit Wnt signaling in normal colonic mucosa as 
indicated by a reduction in the expression of a panel of Wnt 
target genes. This suggests that resveratrol or GP may play 
a beneﬁ  cial role in colon cancer prevention. Further study of 
dietary supplementation with resveratrol and/or whole grapes 
or freeze-dried GP as a potential colon cancer preventive 
strategy is warranted.
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